These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Focus on Fotemustine. De Rossi A; Rossi L; Laudisi A; Sini V; Toppo L; Marchesi F; Tortorelli G; Leti M; Turriziani M; Aquino A; Bonmassar E; De Vecchis L; Torino F J Exp Clin Cancer Res; 2006 Dec; 25(4):461-8. PubMed ID: 17310834 [TBL] [Abstract][Full Text] [Related]
25. The vital link between the ubiquitin-proteasome pathway and DNA repair: impact on cancer therapy. Motegi A; Murakawa Y; Takeda S Cancer Lett; 2009 Sep; 283(1):1-9. PubMed ID: 19201084 [TBL] [Abstract][Full Text] [Related]
26. New radiosensitizing regimens, drugs, prodrugs, and candidates. Vallerga AK; Zarling DA; Kinsella TJ Clin Adv Hematol Oncol; 2004 Dec; 2(12):793-805. PubMed ID: 16166960 [TBL] [Abstract][Full Text] [Related]
28. Therapeutic potential of drugs to modulate DNA repair in cancer. Curtin N Expert Opin Ther Targets; 2007 Jun; 11(6):783-99. PubMed ID: 17504016 [TBL] [Abstract][Full Text] [Related]
29. Stimulation of UV-induced DNA excision repair by chemotherapeutic drugs in cancer patients. Roth M; Rogers S; Roberts SS; Boyle JM; Müller HJ; Weber W Anticancer Res; 1994; 14(3A):809-15. PubMed ID: 8074483 [TBL] [Abstract][Full Text] [Related]
30. Genetic and epigenetic regulations of prostate cancer by genistein. Molinié B; Georgel P Drug News Perspect; 2009 Jun; 22(5):247-54. PubMed ID: 19609462 [TBL] [Abstract][Full Text] [Related]
31. Targeting the DNA damage response in cancer. Ljungman M Chem Rev; 2009 Jul; 109(7):2929-50. PubMed ID: 19545147 [No Abstract] [Full Text] [Related]
32. Targeting epigenetic regulatory mechanisms in cancer chemoprevention. Fay JR; Crowell JA; Kopelovich L Expert Opin Ther Targets; 2005 Apr; 9(2):315-28. PubMed ID: 15934918 [TBL] [Abstract][Full Text] [Related]
33. Targeting DNA repair as a promising approach in cancer therapy. Damia G; D'Incalci M Eur J Cancer; 2007 Aug; 43(12):1791-801. PubMed ID: 17588740 [TBL] [Abstract][Full Text] [Related]
34. The molecular basis of cancer and the development of targeted therapy. Riley LB; Desai DC Surg Clin North Am; 2009 Feb; 89(1):1-15, vii. PubMed ID: 19186227 [TBL] [Abstract][Full Text] [Related]
35. Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future. Showalter SL; Charles S; Belin J; Cozzitorto J; Einstein P; Richards NG; Sauter PK; Kennedy EP; Witkiewicz A; Brody JR; Yeo CJ Expert Opin Drug Deliv; 2010 Mar; 7(3):273-84. PubMed ID: 20201734 [TBL] [Abstract][Full Text] [Related]
36. DNA repair alterations in common pediatric malignancies. Papaefthymiou MA; Giaginis CT; Theocharis SE Med Sci Monit; 2008 Jan; 14(1):RA8-15. PubMed ID: 18160950 [TBL] [Abstract][Full Text] [Related]
37. Role of BRCA1, HSD17B1 and HSD17B2 methylation in breast cancer tissue. Bhavani V; Srinivasulu M; Ahuja YR; Hasan Q Cancer Biomark; 2009; 5(4):207-13. PubMed ID: 19729830 [TBL] [Abstract][Full Text] [Related]
38. Overcoming drug resistance in patients with metastatic breast cancer. Wong ST; Goodin S Pharmacotherapy; 2009 Aug; 29(8):954-65. PubMed ID: 19637949 [TBL] [Abstract][Full Text] [Related]
39. Effect of DNA repair deficiencies on the cytotoxicity of drugs used in cancer therapy - a review. Calderón-Montaño JM; Burgos-Morón E; Orta ML; López-Lázaro M Curr Med Chem; 2014; 21(30):3419-54. PubMed ID: 24934343 [TBL] [Abstract][Full Text] [Related]